Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)

Small Molecules Studied

HMS LINCS ID Name Alternative Names LINCS ID Structure Image PubChem CID
10052-3 Sirolimus
Rapamycin
LSM-1052 5040
10264-1 Methotrexate
Rheumatrex; Trexall; Amethopterin; MTX
LSM-5690 126941
10260-1 Ispinesib
SB-715992
LSM-5732 6851740
10189-2 Bosutinib
SKI-606
LSM-1190 5328940
10282-1 Vorinostat
suberoylanilide hydroxamic acid (SAHA); Zolinza
LSM-3828 5311
10175-3 Sunitinib
Sutent; SU11248
LSM-42800 3086686
10236-1 17-AAG
Tanespimycin
LSM-43239 151069
10247-1 Docetaxel
Taxotere
LSM-6360 148124
10208-2 JNK-IN-5A
TCS JNK 5a; KIN001-188
LSM-1209 766949
10507-1 Disulfiram
Tetraethylthiuram disulfide; TETD
3117
10516-1 Ribavirin
Tribavirin
37542
10223-2 AG1478
Tyrphostin
LSM-1224 2051
10239-1 AG1024
Tyrphostin AG 1024
LSM-4262 2044
10241-1 Bortezomib
Velcade
LSM-6281 387447
10241-4 Bortezomib
Velcade
LSM-6281 387447
10241 Bortezomib
Velcade
LSM-6281 387447
10511-1 Mebendazole
Vermox
4030
10513-1 Nelfinavir
Viracept
64143
10021-5 Tozasertib
VX680; MK-0457
LSM-1021 5494449
10098-2 Gefitinib
ZD1839; Iressa
LSM-1098 123631